These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27936527)

  • 21. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 23. Anticoagulation in cirrhosis patients: what don't we know?
    Northup PG; Intagliata NM
    Liver Int; 2011 Jan; 31(1):4-6. PubMed ID: 21092072
    [No Abstract]   [Full Text] [Related]  

  • 24. Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?
    Pannucci CJ; Rondina MT
    Surgery; 2017 Feb; 161(2):329-331. PubMed ID: 27712881
    [No Abstract]   [Full Text] [Related]  

  • 25. Dosage of enoxaparin among obese and renal impairment patients.
    Bazinet A; Almanric K; Brunet C; Turcotte I; Martineau J; Caron S; Blais N; Lalonde L
    Thromb Res; 2005; 116(1):41-50. PubMed ID: 15850607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
    Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
    Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
    Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary embolism in a morbidly obese patient receiving dabigatran.
    Nasir U
    Clin Cardiol; 2017 Sep; 40(9):777. PubMed ID: 28692741
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
    Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
    Trunfio M; Salvador E; Cabodi D; Marinaro L; Alcantarini C; Gaviraghi A; Trentalange A; Lipani F; Sciascia S; Roccatello D; Bonora S; Di Perri G; Calcagno A;
    Thromb Res; 2020 Dec; 196():432-434. PubMed ID: 33049598
    [No Abstract]   [Full Text] [Related]  

  • 32. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol.
    Adatya S; John R; Eckman PM
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1465-6. PubMed ID: 25983257
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese.
    Hagopian JC; Riney JN; Hollands JM; Deal EN
    Ann Pharmacother; 2013 Dec; 47(12):1641-8. PubMed ID: 24259606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparin in patients with advanced cirrhosis.
    Bechmann LP; Sichau M; Wichert M; Gerken G; Kröger K; Hilgard P
    Liver Int; 2011 Jan; 31(1):75-82. PubMed ID: 20958919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test.
    Silvain J; Beygui F; Ankri A; Bellemain-Appaix A; Pena A; Barthelemy O; Cayla G; Gallois V; Galier S; Costagliola D; Collet JP; Montalescot G
    J Am Coll Cardiol; 2010 Feb; 55(7):617-25. PubMed ID: 20170785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations.
    Barras MA; Duffull SB; Atherton JJ; Green B
    Ther Drug Monit; 2010 Aug; 32(4):482-8. PubMed ID: 20592650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of anticoagulants in morbidly obese patients.
    Domienik-Karłowicz J; Pruszczyk P
    Cardiol J; 2016; 23(1):12-6. PubMed ID: 26412600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.